Healthcare Industry News: cardiac imaging
News Release - September 8, 2006
Positron Corporation to Provide MIMcardiac(TM) Software with mPower(TM) PET ScannersHOUSTON--(HSMN NewsFeed)--Sept. 8, 2006--Positron Corporation (OTCBB:POSC ), a developer and manufacturer of PET medical devices, announced today that it has partnered with MIMvista Corp. to provide MIMcardiac(TM) display and analysis software for their mPower(TM) brand scanners.
MIMcardiac, part of the MIMvista Corporation fusion and display software suite, will provide Positron Corporation's customers the ability to register three dimensional computed tomograph coronary angiograms (3D CTCA) and functional cardiac studies acquired on the mPower scanner, as well as triangulate between 3D and cross-sectional images. Users will also benefit from MIMcardiac's fusion of static and gated functional images including stress/rest metabolism/perfusion studies for evaluation of ischemia and infarction. Automatic calculation of cardiac volumes and ejection fraction are included. The software offering provides improved patient diagnosis and management through comparison of functional and anatomic image volumes.
Joseph Oliverio, president of Positron states, "MIMcardiac software will assist us in marketing our mPower(TM) scanners to the thousands of cardiology groups in the United States. We believe that the future of cardiac diagnostic imaging will involve the fusion of anatomy and metabolism / perfusion. MIMcardiac allows us to immediately offer this powerful combination."
About MIMvista Corporation:
MIMvista is a leading third party software for PET and PET/CT display. Since inception over six years ago, MIMvista Corp. has grown to an unparalleled level of professionalism both with customer relations and skillful engineering, while spanning a customer base across the globe. To learn more about MIMvista Corp., please visit www.mimvista.com.
Positron Corporation designs, manufactures, markets and supports advanced medical imaging devices utilizing positron emission tomography (PET) technology under the trade name POSICAM(TM) systems. POSICAM(TM) systems incorporate patented and proprietary software and technology for the diagnosis and treatment of patients in the areas of cardiology, oncology and neurology. Positron Corporation offers unique combination of low cost technology and disease specific software solutions differentiating themselves from all other medical device manufacturers. POSICAM(TM) systems are in use at leading medical facilities, including the Weatherhead PET center at the University of Texas Health Science Center in Houston, Texas; The Heart Center of Niagara in Niagara Falls, New York; Beth Israel Medical Center, New York; Emory Crawford Long Hospital Carlyle Fraser Heart Center in Atlanta, Georgia; and Nishidai Clinic (Diagnostic Imaging Center) in Tokyo, Japan. Additional information may be found at www.positron.com.
Forward Looking Statements:
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The words "expect," "anticipate," "intend," "plan," "believe," "seek," "estimate," and similar expressions are intended to identify such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (281) 492-7100.
Source: Positron Corporation
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.